Xultophy 100/3.6 and Muscle weakness aggravated - a phase IV clinical study of FDA data

Summary:

Muscle weakness aggravated is reported only by a few people who take Xultophy 100/3.6.

The phase IV clinical study analyzes which people take Xultophy 100/3.6 and have Muscle weakness aggravated. It is created by eHealthMe based on reports of 137 people who have side effects while taking Xultophy 100/3.6 from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 26, 2022

137 people reported to have side effects when taking Xultophy 100/3.6.
Among them, 2 people (1.46%) have Muscle weakness aggravated.


What is Xultophy 100/3.6?

Xultophy 100/3.6 has active ingredients of insulin degludec; liraglutide. eHealthMe is studying from 138 Xultophy 100/3.6 users for its effectiveness, alternative drugs and more.

What is Muscle weakness aggravated?

Muscle weakness aggravated (aggravated lack of muscle strength) is found to be associated with 1,267 drugs and 643 conditions by eHealthMe.

Number of Xultophy 100/3.6 and Muscle weakness aggravated reports submitted per year:

Could Xultophy 100/3.6 cause Muscle weakness aggravated?

Gender of people who have Muscle weakness aggravated when taking Xultophy 100/3.6 *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Muscle weakness aggravated when taking Xultophy 100/3.6 *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common side effects people have besides Muscle weakness aggravated *:

  1. The Flu (the flu is caused by an influenza virus): 1 person, 50.00%
  2. Nausea And Vomiting: 1 person, 50.00%
  3. Nausea (feeling of having an urge to vomit): 1 person, 50.00%
  4. Itching: 1 person, 50.00%
  5. Impaired Driving Ability: 1 person, 50.00%
  6. Feeding Disorder (when children refuse to eat certain food groups): 1 person, 50.00%
  7. Dizziness: 1 person, 50.00%
  8. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure): 1 person, 50.00%
  9. Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 1 person, 50.00%

Common conditions people have *:

  1. Type 2 Diabetes: 1 person, 50.00%
  2. Diabetes: 1 person, 50.00%

* Approximation only. Some reports may have incomplete information.

Do you take Xultophy 100/3.6 and have Muscle weakness aggravated?

Check whether Muscle weakness aggravated is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Muscle weakness aggravated and when was it recovered:

Expand to all the drugs that have ingredients of insulin degludec; liraglutide:

Alternative drugs to, pros and cons of Xultophy 100/3.6:

Muscle weakness aggravated treatments and more:

COVID vaccines that are related to Muscle weakness aggravated:

Common drugs associated with Muscle weakness aggravated:

All the drugs that are associated with Muscle weakness aggravated:

Common conditions associated with Muscle weakness aggravated:

All the conditions that are associated with Muscle weakness aggravated:

How the study uses the data?

The study uses data from the FDA. It is based on insulin degludec; liraglutide (the active ingredients of Xultophy 100/3.6) and Xultophy 100/3.6 (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: